BC Extra | Aug 28, 2019
Clinical News

Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

InDex's UC therapy heading for Phase III  InDex Pharmaceuticals Holding AB (SSE:INDEX) is planning Phase III testing of cobitolimod after the DNA-based immunomodulatory sequence (DIMS) therapy met the primary endpoint in the Phase IIb CONDUCT...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
BC Extra | Feb 10, 2017
Company News

Management tracks

Sanofi (Euronext:SAN; NYSE:SNY) named Kathleen Tregoning EVP of external affairs, effective Feb. 27. She was SVP of corporate affairs at Biogen Inc. (NASDAQ:BIIB). Cell therapy company Juno Therapeutics Inc. (NASDAQ:JUNO) named Corsee Sanders EVP and...
BioCentury | May 30, 2016
Finance

It takes a village

5AM Ventures isn't about to jump on the bandwagon with other early stage biotech venture firms that are raising large funds with the goal of forming smaller syndicates and retaining larger ownership stakes. Instead, the...
BC Week In Review | May 2, 2016
Clinical News

Bevespi Aerosphere glycopyrrolate/formoterol fumarate regulatory update

FDA approved an NDA for twice-daily Bevespi Aerosphere glycopyrrolate/formoterol fumarate from AstraZeneca for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere delivers glycopyrrolate ( PT001 ), a long-acting...
BC Extra | Apr 27, 2016
Company News

FDA approves AZ's Bevespi Aerosphere for COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Bevespi Aerosphere ( PT003 ) for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. Bevespi Aerosphere delivers long-acting muscarinic antagonist (LAMA) glycopyrrolate ( PT001 ) and long-acting...
BioCentury | Jun 15, 2015
Finance

Products, hold the platform

While many VCs are pumping record-breaking amounts of capital into big idea platform companies and urging them to fully explore their technologies, Clarus Ventures is sticking with its more measured approach. In addition to keeping...
BC Innovations | May 14, 2015
Targets & Mechanisms

Sense and sensibility

While bronchodilators and steroids have long been the mainstays of asthma treatment, the dogma has been that the two classes of drugs address distinct processes, airway constriction and inflammation. That hypothesis might be turned on...
BC Extra | Mar 19, 2015
Clinical News

AstraZeneca meets in Phase III COPD trials

AstraZeneca plc (LSE:AZN; NYSE:AZN) said PT003 met the primary endpoint of the Phase III PINNACLE 1 and PINNACLE 2 studies to treat chronic obstructive pulminary disease (COPD). In both trials, PT003 led to statistically significant...
Items per page:
1 - 10 of 59
BC Extra | Aug 28, 2019
Clinical News

Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

InDex's UC therapy heading for Phase III  InDex Pharmaceuticals Holding AB (SSE:INDEX) is planning Phase III testing of cobitolimod after the DNA-based immunomodulatory sequence (DIMS) therapy met the primary endpoint in the Phase IIb CONDUCT...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
BC Extra | Feb 10, 2017
Company News

Management tracks

Sanofi (Euronext:SAN; NYSE:SNY) named Kathleen Tregoning EVP of external affairs, effective Feb. 27. She was SVP of corporate affairs at Biogen Inc. (NASDAQ:BIIB). Cell therapy company Juno Therapeutics Inc. (NASDAQ:JUNO) named Corsee Sanders EVP and...
BioCentury | May 30, 2016
Finance

It takes a village

5AM Ventures isn't about to jump on the bandwagon with other early stage biotech venture firms that are raising large funds with the goal of forming smaller syndicates and retaining larger ownership stakes. Instead, the...
BC Week In Review | May 2, 2016
Clinical News

Bevespi Aerosphere glycopyrrolate/formoterol fumarate regulatory update

FDA approved an NDA for twice-daily Bevespi Aerosphere glycopyrrolate/formoterol fumarate from AstraZeneca for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere delivers glycopyrrolate ( PT001 ), a long-acting...
BC Extra | Apr 27, 2016
Company News

FDA approves AZ's Bevespi Aerosphere for COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Bevespi Aerosphere ( PT003 ) for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. Bevespi Aerosphere delivers long-acting muscarinic antagonist (LAMA) glycopyrrolate ( PT001 ) and long-acting...
BioCentury | Jun 15, 2015
Finance

Products, hold the platform

While many VCs are pumping record-breaking amounts of capital into big idea platform companies and urging them to fully explore their technologies, Clarus Ventures is sticking with its more measured approach. In addition to keeping...
BC Innovations | May 14, 2015
Targets & Mechanisms

Sense and sensibility

While bronchodilators and steroids have long been the mainstays of asthma treatment, the dogma has been that the two classes of drugs address distinct processes, airway constriction and inflammation. That hypothesis might be turned on...
BC Extra | Mar 19, 2015
Clinical News

AstraZeneca meets in Phase III COPD trials

AstraZeneca plc (LSE:AZN; NYSE:AZN) said PT003 met the primary endpoint of the Phase III PINNACLE 1 and PINNACLE 2 studies to treat chronic obstructive pulminary disease (COPD). In both trials, PT003 led to statistically significant...
Items per page:
1 - 10 of 59